Background An increasing number of studies evidences that amyotrophic lateral sclerosis (ALS) is characterized by extensive alterations in different cell types and in different regions besides the CNS. We previously reported the upregulation in ALS models of a gene called fibroblast-specific protein-1 or S100A4, recognized as a pro-inflammatory and profibrotic factor. Since inflammation and fibrosis are often mutual-sustaining events that contribute to establish a hostile environment for organ functions, the comprehension of the elements responsible for these interconnected pathways is crucial to disclose novel aspects involved in ALS pathology. Methods Here, we employed fibroblasts derived from ALS patients harboring the C9orf72 hexanucleotide repeat expansion and ALS patients with no mutations in known ALS-associated genes and we downregulated S100A4 using siRNA or the S100A4 transcriptional inhibitor niclosamide. Mice overexpressing human FUS were adopted to assess the effects of niclosamide in vivo on ALS pathology. Results We demonstrated that S100A4 underlies impaired autophagy and a profibrotic phenotype, which characterize ALS fibroblasts. Indeed, its inhibition reduces inflammatory, autophagic, and profibrotic pathways in ALS fibroblasts, and interferes with different markers known as pathogenic in the disease, such as mTOR, SQSTM1/p62, STAT3, α-SMA, and NF-κB. Importantly, niclosamide in vivo treatment of ALS-FUS mice reduces the expression of S100A4, α-SMA, and PDGFRβ in the spinal cord, as well as gliosis in central and peripheral nervous tissues, together with axonal impairment and displays beneficial effects on muscle atrophy, by promoting muscle regeneration and reducing fibrosis. Conclusion Our findings show that S100A4 has a role in ALS-related mechanisms, and that drugs such as niclosamide which are able to target inflammatory and fibrotic pathways could represent promising pharmacological tools for ALS.

An accurate approach to coral disease study is critical for understanding the global decline of coral populations. Such an approach should involve the proper use of medical concepts and terminology to avoid confusion and promote clarity in the coral disease literature. Inflammatory and neoplastic disorders have been frequently confused in corals. They are both reported as ‘growth anomalies’ because of their possible gross similarity, but in fact they are very different types of lesions and pathologic phenomena. In this work, we assessed the distribution and prevalence of growth anomalies, externally visible as nodular-like lesions, in the soft corals Eunicella cavolinii and E. singularis in 2008-2009 in 3 different areas along the Campanian coastline of Italy. Histopathology revealed them as chronic inflammatory lesions, resembling chronic inflammatory lesions of vertebrates, encapsulating an unidentified pathogen. Congo red and Masson Fontana histochemistry highlighted an amoebocyte infiltration with the presence of new apposition of melanin coupled with amyloid sheets intended as part of the defensive response, as reported in other invertebrates. A parallel molecular analysis of 16S rRNA of the lesions suggested that the causative agent is an endolithic cyanobacterium belonging to the order Nostocales. This is the first study assessing the presence of amyloid fibrils in corals.